HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following receipt ...
SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...
HeartBeam (BEAT) announced its regulatory strategy following receipt of a Not Substantially Equivalent, or NSE, decision on the company’s 510(k) ...
As the medical community continues to advance in both technology and technique, the importance of precise 12 lead ECG placement in diagnosing cardiovascular conditions has come into sharper focus.
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
While electrocardiograms are often the first test ordered to diagnose heart disease, they’re not as accurate as many think. Ennovea Medical is cutting down on electrode placement errors with a ...
You should keep in mind that there are a lot of symptomatic cardiac patterns that you can't tell from a single-lead ECG. A full workup involves twelve leads positioned strategically on the chest. The ...
Life science educators across universities and healthcare training institutions are placing increasing emphasis on accurate clinical skills training, particularly for procedures that rely on precise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback